Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9699056 | 0.91 | PDE4B (0.40) | NPC1UCHL1SCN4AEPHX2USP30 | |
| SCHEMBL30439876 | 0.91 | HSD17B10 (0.40) | NPC1HSD17B10UCHL1EPHX2LMNA | |
| SCHEMBL3626968 | 0.85 | HSD17B10 (0.46) | NPC1HSD17B10UCHL1LMNANPSR1 | |
| SCHEMBL10296209 | 0.85 | NPC1 (0.41) | NPC1HSD17B10UCHL1LMNANPSR1 | |
| SCHEMBL31603663 | 0.85 | MEN1 (0.42) | HSD17B10 | |
| SCHEMBL4717013 | 0.83 | HSD17B10 (0.44) | NPC1HSD17B10UCHL1LMNANPSR1 | |
| SCHEMBL4397346 | 0.82 | NPC1 (0.39) | NPC1HSD17B10UCHL1LMNANPSR1 | |
| SCHEMBL17977808 | 0.80 | UCHL1 (0.44) | NPC1UCHL1USP30LMNANPSR1 | |
| SCHEMBL5225900 | 0.79 | ATM (0.38) | NPC1HSD17B10UCHL1SCN4AUSP30 | |
| SCHEMBL5225895 | 0.79 | ATM (0.38) | NPC1HSD17B10UCHL1SCN4AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11078192-B2 | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. | 2021-08-03 | — | — | US | disclosed |
| US-20190308957-A1 | AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | US | disclosed |
| EP-2913324-B1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2017-12-20 | — | — | EP | disclosed |
| US-9637454-B2 | Fluorine substituted cyclic amine compounds and preparation methods, pharmaceutical compositions, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MADICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-05-02 | — | — | US | disclosed |
| US-20150284331-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-08 | — | — | US | disclosed |
| EP-2913324-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-09-02 | — | — | EP | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | NPC1 486/4885HSD17B10 1511/4885UCHL1 4515/4885 |
| US-20150284331-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ACHE, BCHE, CHRM3 | NPC1 625/4885HSD17B10 505/4885UCHL1 509/4885 |
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | NPC1 503/4885HSD17B10 3264/4885UCHL1 3670/4885 |
| US-20190308957-A1 | AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDCD1, CD274, PDCD1LG2 | NPC1 1757/4885HSD17B10 1371/4885UCHL1 515/4885 |
| US-11078192-B2 | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | PDCD1, CD274, PDCD1LG2 | NPC1 1757/4885HSD17B10 1371/4885UCHL1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.